BOOM
Citations are updated once a week. Recently added citations may not appear.
| Context | Citation |
|---|---|
| Limosilactobacillus reuteri {L. Reuteri} - Escherichia coli HVH 100 (4-2850729) |
👶
Exopolysaccharides from camel milk-derived Limosilactobacillus reuteri C66: Structural characterization, bioactive and rheological properties for food applications. Food chemistry: X (Food Chem X ) Vol: 25 Issue Pages: 102164 Pub: 2025 Jan Epub: 2025 Jan 27 Authors Kober AKMH , Abdin M , Subhash A , Liu SQ , Dertli E , Abu-Jdayil B , Show PL , Ayyash M , Html Article Publication |
| Limosilactobacillus reuteri {L. Reuteri} - Escherichia coli HVH 100 (4-2850729) |
👶
Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study. Frontiers in cellular and infection microbiology (Front Cell Infect Microbiol ) Vol: 14 Issue Pages: 1401462 Pub: 2024 Epub: 2024 Jul 18 Authors Tantibhadrasapa A , Li S , Buddhasiri S , Sukjoi C , Mongkolkarvin P , Boonpan P , Wongpalee SP , Paenkaew P , Sutheeworapong S , Nakphaichit M , Nitisinprasert S , Hsieh MH , Thiennimitr P , Html Article Publication |
| Limosilactobacillus reuteri {L. Reuteri} - Escherichia coli HVH 100 (4-2850729) |
👶
Antimicrobial properties of Limosilactobacillus reuteri strains for control of Escherichia coli and Salmonella strains, diarrhoea cause in weaning pigs. Veterinarni medicina (Vet Med (Praha) ) Vol: 68 Issue 5 Pages: 191-199 Pub: 2023 May Epub: 2023 May 29 Authors Yoo Y , Lee J , Cho J , Yoon Y , Html Article Publication |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
